![Page Image](https://mumcdnstorage.blob.core.windows.net/bct/2022/11/Mantle-Cell-Lymphoma_210x210.png)
Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Advertisement
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
Granted under FDA Priority Review, the approval is based on results from the MCL cohort of the TRANSCEND NHL 001 study.
Dr. Maddocks hopes that current trials will help us “spring forward” into a chemotherapy-free approach to treating MCL.
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Narazaciclib plus ibrutinib regulated signatures associated with DNA repair, P53 signaling, and glycolytic activity.
Progression-free survival was significantly prolonged with the combination compared with a placebo.
The trial established the recommended phase II dose of acalabrutinib, venetoclax, and obinutuzumab.
Compared to past studies, acalabrutinib plus rituximab improves post-chemotherapy induction CR rates and MRD negativity.
The median overall survival was 44.9 months with ibrutinib plus venetoclax versus 38.6 months with ibrutinib plus placebo.
The data came from ZUMA-2, a phase II, open-label, multicenter, single-arm trial in which participants received brexu-cel.
The study evaluated ROR1 expression levels in a panel of MCL cell lines and primary patient samples.
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK.
Study authors noted that the findings underscore the need for tailored approaches to MRD testing.
Jonathon B. Cohen, MD, MS, reported these updated results from the BRUIN trial.
Those high-risk disease features include high proliferation index, TP53 mutation, blastoid morphology, and CNS lymphoma.
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Mosunetuzumab plus polatuzumab vedotin achieved high CR rates in relapsed or refractory MCL with prior BTKi treatment.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters: